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At the time of diagnosis, 20% of patients with colorectal cancer present
metastasis. Among individuals with primary lesions, 50% of them will
develop distant tumours with time. Therefore, early diagnosis and predic-
tion of aggressiveness is crucial for therapy design and disease prognosis.
Tumoral cells must undergo significant changes in energy metabolism to
meet increased structural and energetic demands for cell proliferation, and
metabolic alterations are considered to be a hallmark of cancer. Here, we
present the ATP-binding cassette transporter (ABCA1), a regulator of
cholesterol transport, as a new marker for invasion and colorectal cancer
survival. ABCA1 is significantly overexpressed in patients at advanced
stages of colorectal cancer, and its overexpression confers proliferative
advantages together with caveolin-1 dependent-increased migratory and
invasive capacities. Thus, intracellular cholesterol imbalances mediated by
ABCA1 overexpression may contribute to primary tumour growth and dis-
semination to distant locations. Furthermore, we demonstrate here that
increased levels of apolipoprotein A1 (APOA1), a protein involved in
cholesterol efflux and high-density lipoprotein constitution, in the extracel-
lular compartment modulates expression of ABCA1 by regulating COX-2,
and compensate for ABCA1-dependent excessive export of cholesterol.
APOA1 emerges as a new therapeutic option to inhibit the promotion of
colorectal cancer to metastasis by modulating intracellular cholesterol
metabolism. Furthermore, we propose apabetalone, an orally available
small molecule that is currently being evaluated in clinical trials for the
treatment of atherosclerosis, as a new putative therapeutic option to pre-
vent colorectal cancer progression by increasing APOA1 expression and
regulating reverse transport of cholesterol.
Abbreviations
ABCA1, ATP-binding cassette transporter; APOA1, apolipoprotein A1; CAV-1, caveolin-1; CI, confidence interval; CMS, consensus molecular
subtypes; COX-2, cyclooxygenase 2; CRC, colorectal cancer; DMEM, Dulbecco0s modified Eagle medium; E-cad, E-cadherin; EMT, epithelial-
to-mesenchymal transition; FA, fatty acids; hAPOA1, human recombinant RNA against apolipoprotein A1; HDL, high-density lipoprotein; LN,
lymph node; MbCD, methyl-b-cyclodextrin; NoORF, no open reading frame; RCT, reverse cholesterol transport; SI, stage I-colorectal cancer;
SII, stage II-colorectal cancer; SIII-CRC, stage III-colorectal cancer; SIV, stage IV-colorectal cancer; VIM, vimentin.
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1. Introduction
Cancer is the second leading cause of mortality and is
responsible of one sixth of deaths worldwide. Among
the global leading causes of cancer death and consider-
ing both sexes, colorectal cancer (CRC) occupies the
fourth position after lung, liver and stomach cancer
(WHO, 2012). Although the 5-year survival after diag-
nosis when metastasis is already present has improved
in the last decade, this improvement is still less than 3%
(Steeg, 2016). In most cases, early detection allows
tumours to be successfully removed by surgery and
increases treatment efficiency. Thus, an early diagnosis
and prediction of aggressiveness becomes of vital impor-
tance for therapy design and disease prognosis. During
tumorigenesis, a cascade of alterations affecting the
expression of oncogenes and tumour suppressors takes
place in the body of the patients. Together with this, sig-
nificant changes in energy metabolism are needed to
respond to new requirements of tumoral cells to sustain
increased structural, energetic and biosynthesis precur-
sor demands for cell proliferation (Cantor and Sabatini,
2012). Although metabolic alterations encountered in
tumours are nowadays considered a hallmark of cancer
(Hanahan and Weinberg, 2011), knowledge of fatty acid
(FA) synthesis and lipid metabolism alterations during
tumorigenesis is still slight. ATP-binding cassette trans-
porter (ABCA1) is a transmembrane protein responsible
for reverse cholesterol transport (RCT) from the inner
cell to circulatory system (Oram and Lawn, 2001). By
interacting with ABCA1, apolipoprotein A1 (APOA1)
is able to recover the extracted cholesterol and syn-
thethize high-density lipoproteins (HDL) (Wang and
Tall, 2003). Both the overexpression and the downregu-
lation of ABCA1 have been associated with tumorigene-
sis (Bi et al., 2016; Chou et al., 2015; Hedditch et al.,
2014; Lee et al., 2013; Smith and Land, 2012; Vargas
et al., 2015). Importantly, this cholesterol transporter is
one of the members of a lipid metabolism signature
related to poor prognosis in patients diagnosed with
stage II colorectal cancer (SII-CRC). This signature,
ColoLipidGene, encompasses the transcriptional activa-
tion of four metabolism-related genes: ACSL1, ABCA1,
AGPAT1 and SCD (Vargas et al., 2015). A meta-analy-
sis performed in our laboratory with more than 1000
patients, demonstrated that ABCA1 is the only member
of the ColoLipidGene signature whose overexpression
by itself represents a significant association with overall
survival in CRC (Fernandez et al., 2017). It is our aim
to understand the importance of ABCA1 and choles-
terol transport regulation in CRC dissemination during
advanced stages of the disease and its potential as a
therapeutic target. BET inhibitors have been proposed
as suppressors of tumorigenesis in several types of can-
cers (Cheng et al., 2013; Puissant et al., 2013; Shi et al.,
2014); among these, apabetalone (RVX-208; Resver-
logix, Calgary, Canada; T3E6L1) is the most advanced
in terms of clinical development. For the first time, we
demonstrate here the potential of apabetalone as a regu-
lator of ABCA1 and the reverse cholesterol transport.
By promoting APOA1 transcription, we propose here a
new strategy based on apabetalone treatment to avoid
CRC progression to invasive stages of cancer.
2. Materials and methods
2.1. Patients and samples
In all, 100 formalin-fixed, paraffin-embedded samples
from La Paz University Hospital were obtained with the
understanding and written consent of each patient and
with the approval of the human research Ethics Review
Committee of La Paz University Hospital (HULP-PI-
1452). The methodologies in this study conformed to
the standards set by the Declaration of Helsinki. Inclu-
sion criteria were the following: age ≥18, completely
resected rectal cancer or colon adenocarcinoma located
at ≥15 cm from the anal verge as determined by endo-
scopy or above the peritoneal reflection in the surgical
resection, confirmed stage II AJCC/UICC primary
CRC and follow-up of at least 36 months.
2.2. Generation of stable cell lines and drug
treatments
DLD-1 (CCL-221TM) and Caco-2 (HTB-37TM) were pur-
chased from the American Type Culture Collection
(ATCC, Manassas, VA, USA). Lentiviruses were pro-
duced in HEK293T cells. Selection was performed over
12 days by adding 2 lgmL1 puromycin and 3 lgmL1
blasticidin (Sigma-Aldrich, Alcobendas, Spain) for no
open reading frame (NoORF and ABCA1 constructs,
respectively. Methyl-b-cyclodextrin (MbCD) was pur-
chased from Sigma (Cat. C4555). Human recombinant
apolipoprotein A1 (hAPOA1) (Sigma-Aldrich; Cat.
SRP.4693) was used in a final concentration of
40 lgmL1. The absence of mycoplasma was confirmed
by PCR every second week.
2.3. Three-dimensional cell culture
A total of 10 000 cells were suspended in a mix of Dul-
becco0s modified Eagle medium (DMEM; Lonza. Cul-
tek S.L.U, Madrid, Spain), 10% FBS and Matrigel
Growth Factor Reduced Basement Membrane Matrix
(Corning; Cat. 356230) (20% of cells and 80% of
Matrigel). Pictures were taken every 24 h using a
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Leica DM IL microscope and registered using LAS soft-
ware (L’Hospitalet de Llobregat, Barcelona, Spain).
2.4. Cholesterol efflux assay
Intracellular cholesterol and cholesterol present in cul-
ture medium was measured using the Cholesterol Efflux
Fluorometric Assay Kit (Cat. K582-100; BioVision, Inc.,
Milpitas, CA, USA)
2.5. Cell proliferation assays
xCELLigence (ACEA Biosciences, Inc., Izasa Scienti-
fic, L’Hospitalet de Llobregat, Barcelona, Spain) was
used to analyze cell proliferation. Ten thousand cells
were seeded in 16-well E-plates (Cat. 05469830001),
and a time-lapse experiment was performed with the
real-time cell analysis instrument. Graphical represen-
tations were designed and statistically analyzed with
GRAPHPAD PRISM software (La Jolla, CA, USA).
2.6. Migration and invasion assays
Crystal violet staining was performed in cells grown in
Corning BioCoatTM Control Inserts 8 mm PET mem-
brane (cat. 354578) and in a Corning BioCoatTM Matri-
gel invasion chamber (cat. 354480). Images were
captured using an Olympus CKX41 microscope (Olympus
Iberia S.A.U, L’Hospitalet de Llobregat, Barcelona,
Spain) with 209 LCAch objective and GETIT software
(Olympus) was used for the acquisition. Migration and
invasion were quantified using IMAGEJ software (National
Institutes of Health, Bethesda, MD, USA), and statistical
analysis was performed with GRAPHPAD PRISM software.
2.7. Immunofluorescence and focal adhesion
quantification
Cells were fixed in 4% paraformaldehyde-PBS (Santa
Cruz Biotechnology, CAS30525-89-4, Madrid, Spain)
and blocked with 10% FBS. Primary antibodies were
incubated overnight. After 45 min at room tempera-
ture, secondary antibodies (Alexa 488, Alexa 594;
1 : 1000) were harvested and cells were rinsed with
PBS-Triton 0.03%. Images were captured using a Leica
DM IL microscope and registered using LAS software.
For the quantification of FA sizes, the protocol previ-
ously published by Utku Horzum and collaborators
was followed (Horzum et al., 2014). The localization of
ABCA1 and a-sodium potassium ATPase was studied
with a Leica SP5 Confocal Microscope.
2.8. Biochemical analysis and quantitative PCR
For immunoblotting, cells were lysed with Laemmli
buffer. Measurements of APOA1 concentration were
done by ELISA following the recommendations of the
supplier (Abcam, Cambridge, UK; ab108804). RNA
was extracted using Tri Reagent (Sigma-Aldrich).
Quantitative real-time PCR was performed in the
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Fig. 1. ABCA1, a new putative marker for CRC prognosis. (A) ABCA1 mRNA expression in SII-CRC and SIII-CRC patients. (B) Correlation
between ABCA1 expression and carcinoembryonic antigen. (C) ABCA1 mRNA levels of expression correlated with disease-free survival
(DFS) in SII-CRC (left-hand panel) and SIII-CRC patients (right-hand panel).
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QuantStudio 12K Flex System Real-Time PCR System
(Life Technologies, Alcobendas, Spain). Values were
corrected by GAPDH expression. The 2ΔΔCt method
was applied to calculate the relative gene expression.
2.9. Antibodies
The following antibodies were used: mouse monoclonal
ABCA1 antibody (AB.H10; Abcam. Cat. ab18180;
Abcam); anti-apolipoprotein AI antibody (EP1368Y;
Abcam. Cat. ab52945); rabbit polyclonal caveolin-1
antibody (Cat. Abcam. ab2910); monoclonal anti-alpha-
tubulin, clone DM1A (Sigma-Aldrich. Cat. T9026);
purified mouse anti-E-cadherin (BD Biosciences. Cat.
610182, San Agustın de Guadalix, Madrid, Spain);
mouse monoclonal anti-vimentin (Progen. Cat. 61013,
Heidelberg, Germany); rabbit polyclonal phospho-
histone H3 (Ser10) (Cell Signaling. Cat. D2C8,
L ’Hospitalet de Llobregat, Barcelona, Spain); mouse
monoclonal RHOA antibody (1B12; Abcam. Cat.
54835); mouse monoclonal Anti-alpha 1 Sodium Potas-
sium ATPase antibody [464.6]; Abcam. Cat. ab7671.
2.10. Statistical analysis
The significance of the differences between groups was
determined by t-test. All reported P-values were two-
sided. The statistical analysis was performed using
GRAPHPAD PRISM software: n.s. P > 0.05; *P < 0.05;
**P < 0.01; ***P < 0.001; ****P < 0.0001.
3. Results
3.1. ABCA1 as a putative marker for colorectal
cancer malignancy
Stage II of colorectal cancer is characterized by invasion
of the muscularis propria and/or subserosa, non-perito-
nealized pericolic or perirectal tissue, with no invasion
of lymph nodes. In contrast, stage III patients (SIII-
CRC) always display at least one lymph node affected
with no distant metastasis. To evaluate the importance
of ABCA1 regulation in CRC staging, we analyzed
mRNA expression in 71 SII-CRC and 66 SIII-CRC
patients (University Hospital La Paz, Madrid). Expres-
sion of ABCA1 mRNA was assessed by quantitative
real-time PCR, and we confirmed a significant increase
in SIII-CRC patients (Fig. 1A). Together with other
markers, the carcinoembryonic antigen is used in the
surveillance of CRC patients as a clinical parameter for
prognosis determination (Duffy, 2001; Goldstein and
Mitchell, 2005; Thomson et al., 1969). In our patient
cohorts, we found a weak positive correlation between
ABCA1 and pre-operatory circulatory levels of
carcinoembryonic antigen (Fig. 1B). No correlation
with disease-free survival was found in either SII-CRC
or SIII-CRC patients (Fig. 1C). When other clinical fea-
tures were analyzed, we found no correlation with
ABCA1 levels (Table 1). In a previous work published
by our laboratory, the authors performed a meta-analy-
sis to determine whether ABCA1 gene expression was
associated with death in 1073 CRC patients at all the
stages of the disease [from stage I CRC (SI-CRC) to
stage IV CRC (SIV-CRC)]. Notably, ABCA1 expression
had a risk effect on overall survival, and the pooled
Hazard ratio (HR) was 1.29 [95% confidence interval
(CI) 0.99–1.69]. In the same direction, expression of the
cholesterol transporter increased risk of recurrence in
patients from stages I to III [HR = 1.86 (95% CI 1.37–
2.53) (Fernandez et al., 2017)]. These data, together with
the results that we present here, allow us to postulate
ABCA1 as a new putative marker whose levels of expres-
sion could be used as a prognostic biomarker in CRC
patients.
3.2. ABCA1 overexpression confers proliferative
advantages, promotes epithelial-to-mesenchymal
transition (EMT) and leads to increased
invasiveness
To decipher the molecular mechanisms behind the
association between the expression of the cholesterol
transporter and CRC prognosis, two stable cells lines,
Table 1. Levels of ABCA1 mRNA are represented as the mean of
all the patients together with the standard error of the mean.
Statistical significance is shown for each stage after comparing
parameters. The comparison is made between less malignant and
more malignant situations.
Clinical features ABCA1 mRNA P-value
TNM stage
Stage II 0.01995  0.002115 <0.0001
Stage III 0.1326  0.01892
Primary tumour (T)
T2/3 0.1308  0.01640 0.1556
T4 0.09311  0.02623
Affected LN
0-3 0.1053  0.01495 0.2940
≥4 0.1176  0.02080
Perforation
Negative 0.1171  0.01507 0.7321
Positive 0.1056  0.02956
Vascular invasion
Negative 0.1134  0.01526 0.8897
Positive 0.1173  0.01526
Lymphatic invasion
Negative 0.1033  0.01483 0.2703
Positive 0.1338  0.02551
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Fig. 2. ABCA1 overexpression in two human CRC-derived cell lines. (A) mRNA and ABCA1 protein levels in DLD1 and Caco-2 cells
transduced for ABCA1 overexpression. Control cell line was transduced with an empty vector containing a DNA fragment with no open
reading frame (NoORF). The values in the histograms correspond to mean  SEM. DLD1_NoORF: 1.000  3.576e-007; DLD1_ABCA1:
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included. (D) Cholesterol efflux in DLD1 and Caco-2 stable cell lines. n = 3; for each experiment every condition was analyzed in triplicate.
The values in the histograms correspond to mean  SEM. Significance between groups was determined by t-test. DLD1_NoORF:
1.129  0.1289; DLD1_ABCA1: 1.213  0.2134. Caco-2_NoORF: 1.000  1.654e-005; Caco-2_ABCA1: 1.342  0.08448.
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Caco-2 and DLD1, were generated. Basal levels of
ABCA1 in Caco-2 are significantly higher than those
displayed by DLD1 cells (Fig. S1A); however, levels
of expression of the APOA1 are also increased when
we compare Caco-2 with DLD1 cells (Fig. S1A).
DLD1 and Caco-2 cells were transduced with exoge-
nous human ABCA1 (Figs 2A and S1B). First, the
localization of the protein was analyzed by
immunofluorescence. In Caco-2 cells, the endogenous
protein was detectable in the nucleus of control cells.
Upon overexpression, levels of ABCA1 were increased
in the nuclear compartment and were detectable in
cytoplasmic vesicles (Fig. 2B). Although in DLD1
cells that overexpressed ABCA1 the localization was
mainly cytoplasmic, the protein was also detectable at
the plasma membrane and at the nucleus (Fig. 2C).
High levels of the transporter led to a significant
increase in APOA1-dependent cholesterol efflux,
demonstrating the functionality of exogenous ABCA1
(Fig. 2D). Next, proliferation and cell viability were
monitored in a real-time experiment applying
xCELLigence technology. Overexpression of ABCA1
resulted in a significant increase in cell proliferation
(Fig. 3A). Together with this, 3.3% of DLD1_
NoORF cells were positive for histone H3 phosphory-
lation (3.244  0.53119), whereas up to 5.4% of
DLD1_ABCA1 displayed positive staining
(5.400  0.5669). An increased percentage of prolifer-
ating cells was also found in Caco-2_ABCA1 cells
(Fig. S1C). To achieve malignancy, cells need to
downregulate a battery of genes as well as activate the
expression of some others in a process called EMT
(Kalluri and Weinberg, 2009). We analyzed the levels
of E-cadherin (E-CAD) and vimentin (VIM), two clas-
sical markers of EMT. Both protein and mRNA levels
of E-cad were significantly lower in DLD1_ABCA1,
whereas there was a significant increase in Vim levels
(Fig. 3B). When Caco-2 cells were monitored for
mRNA levels of these markers, we observed a signifi-
cant decrease in E-cad in parallel with a mislocaliza-
tion of the protein. Together with this, a significant
decrease in the levels of Vim was present in Caco-
2_ABCA1 cells (Fig. S1D). Performing classical tran-
swell assays, we observed a six-fold increase in
DLD1_ABCA1 migration capacity compared with
control cells (Fig. 3C; left-hand panel). When Caco-2
cells were monitored, a highly significant increase was
also observed (Fig. 3C). Importantly, when the same
experiment was performed using transwells coated
with collagen, we confirmed an increased invasiveness
in both cell lines overexpressing ABCA1 (Fig. 3B;
right-hand panel). Thus, ABCA1 could favour tumori-
genesis by promoting the growth of the primary
tumour, by increasing proliferation and the formation
of distant lesions, by inducing EMT and by the subse-
quent mobilization of tumour cells.
3.3. ABCA1 overexpression favours spheroid
formation and promotes invasion in a three-
dimensional in vitro model
To monitor cell malignancy in a system that better rep-
resents in vivo conditions, we developed spheroids
derived from our stable cell lines. Single cells overex-
pressing ABCA1 (Fig. S2A) were embedded in base-
ment membrane matrices containing laminin, collagen
IV, heparin sulfate proteoglycans, entactin/nidogen,
and a number of growth factors (MatrigelTM). First, we
observed a growth advantage in both DLD1 and Caco-
2 overexpressing ABCA1 when compared with control
cells, together with an increase in the mitotic population
(Figs 4A and S2B). Next, we interrogated our spheroids
for invasiveness. Cells need to develop invadopodia and
degrade the extracellular matrix during invasion. Thus,
to understand whether ABCA1 overexpression leads to
increased invasion in MatrigelTM, we analyzed the num-
ber and the length of the invadopodia present in each
sphere. The number of protrusions per spheroid was
higher in those spheroids derived from DLD1_ABCA1
(Fig. 4B; left-hand panel). By measuring the longest
protrusion in each spheroid, we demonstrated that the
length was significantly increased in cells overexpressing
the transporter (Fig. 4B; right-hand panel). When
Caco-2 were monitored, the overexpression of ABCA1
promoted the development of protrusions, whereas no
significant differences were found when the length was
measured (Fig. S2C). Together with this, statistically
significant differences were found in E-cad and Vim
Fig. 3. ABCA1 overexpression gives proliferative advantages, promotes EMT and favours invasion. (A) Cell proliferation assay in cells overex-
pressing ABCA1. n = 3. The values in the histograms correspond to mean  SEM. The significance of differences between experimental groups
was determined by t-test. (B) Protein localization and mRNA levels of expression of two well established markers for EMT, E-cad (red) and Vim
(green). DNA is shown in blue (DAPI). N = DLD1_NoOF; B = DLD1_ABCA1. Scale bar corresponds to 20 lm. The values in the histograms
correspond to mean  SEM. The significance of the differences between experimental groups was determined by t-test. (C) Quantification of
cell migration (left-hand panel) and cell invasion (right-hand panel) in DLD1 and Caco-2 cells overexpressing ABCA1 and compared with control
cells. n = 3. For each experiment, every condition was analyzed in duplicate; six fields per condition were quantified. Mean  SEM is
represented in the histograms. The significance between groups was determine by t-test analysis.
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levels of expression (Fig. 4C). Together, these data sup-
port our previous results obtained in two-dimensional
cultures, suggesting that overexpression of ABCA1
could be associated with increased invasive capacities in
colorectal cancer-derived cells.
3.4. Increased malignancy of CRC cells
overexpressing ABCA1 is dependent on caveolin-
1 (CAV-1) and cholesterol transport
Caveolae were proposed to be part of the complex regu-
lating cholesterol efflux and to be the principal location
at which plasma membrane cholesterol is exchanged
between HDL and cells membrane (Luo et al., 2010;
Qin et al., 2016). Increased transcription of ABCA1
was associated with CAV-1 stabilization in prostate
cancer-derived cells (Cohen et al., 2004; Her et al.,
2013). We confirmed that CAV-1 protein levels were
higher in cells overexpressing the cholesterol trans-
porter, whereas mRNA levels were comparable to con-
trol cells (Figs 5A and S3A). Together with this, an
increase in caveolae formation was observed by immun-
odetection in DLD1_ABCA1 cells, as shown in the
right-hand panels of Fig. 5A. By RHOA activation,
CAV-1 is implicated in focal adhesion stability and
turnover (Goetz et al., 2008; Grande-Garcıa et al.,
2007). In our system, ABCA1 not only stabilized CAV-
1 but also caused an increase in total RHOA protein
levels (Fig. 5A). CAV-1 is already known to be impli-
cated in migration by increasing focal adhesion turn-
over, polarization, velocity, persistence and
directionality (Urra et al., 2012). Thus, we wondered
whether ABCA1 was able to regulate focal adhesion
formation through stabilization of CAV-1. By vinculin
immunodetection, we analyzed the status of focal adhe-
sions in our model. Cells overexpressing ABCA1 dis-
played a non-significant increase in the number of focal
adhesions (Fig. S3B). Notably, in DLD1_ABCA1 and
Caco-2_ABCA1 cell lines, vinculin-dependent adhesion
sites became larger, with an average fold increase of
1.228  0.0323 (Fig. 5B, upper panel) and
1.244  0.01248, respectively (Fig. 5B, lower panel).
When patient samples were analyzed, no correlation
between ABCA1 and CAV-1 expression was observed
in SII-CRC (Fig. 5C). Importantly, a moderate positive
correlation between the expression of both mRNAs was
observed in SIII-CRC (Fig. 5C). Thus, ABCA1 overex-
pression might lead to a stabilization of CAV-1 protein
in patients with colorectal cancer, leading to increased
invasive capacities of tumour cells. To further confirm
the dependence of CAV-1 regulation in cell malignancy,
we used the protein inhibitor MbCD to disrupt caveo-
lae and repress CAV-1 expression. Addition of the drug
in DLD1_NoORF produced a reduction in 56% of
CAV-1 protein levels. This reduction was compromised
when DLD1_ABCA1 were treated (72% of CAV-1)
(Fig. 5D). Neither control or ABCA1-overexpressing
cells displayed any significant differences in prolifera-
tion when treated with MbCD (data not shown).
MbCD treatment did not affect migration in control
cells; however, the drug significantly reduced
DLD1_ABCA1 and Caco-2_ABCA1 migrating capaci-
ties (Fig. 5E). For DLD1 cells, we also confirmed a
treatment-dependent significant decrease in the invasive
phenotype. Whereas no significant rescue was found in
Caco-2 control cells, a decreasing tendency was found
in Caco-2_ABCA1 (Fig. 5E). Together with these phe-
notypes, inhibition of CAV-1 provoked a highly signifi-
cant decrease in the size of focal adhesions (Fig. 5F).
Thus, malignant phenotypes derived from ABCA1
overexpression are dependent on CAV-1 stability and
its role as a focal adhesion regulator.
3.5. APOA1 overexpression or exogenous human
recombinant APOA1 inhibit cyclooxygenase 2
(COX-2) expression and decrease malignant
properties driven by ABCA1 overexpression
Considering the essential contribution of APOA1 in
RCT, we investigated the role of this apolipoprotein in
Fig. 4. ABCA1 overexpression favours spheroid formations and promotes invasion in a three-dimensional model. (A) Representative images
of cell growth in a spheroid formation assay in basement membrane matrices (MatrigelTM). Scale bar corresponds to 50 lm. Growth of
DLD1 spheres is represented in the middle panel. The graph presents the average of 30 different spheres. The percentages of cells that
were positive for histone H-3 phosphorylation are presented in the dot plot graph. n = 3; 10 pictures per condition were taken and
quantified. The values in the histograms correspond to mean  SEM. The significance of differences between experimental groups was
determined by t-test. DLD1_NoORF: 3.311  0.6882; DLD1_ABCA1: 5.736  0.7247. (B) The percentage of spheroids that present
protrusions is shown in the left-hand panel. The values in the histograms correspond to mean  SEM. ANOVA analysis was performed to
determine the significance of differences between groups (F(4,9) = 6.146; P = 0.0115). In the dot plot graph, quantification of the longest
protrusions per spheroid are represented. A t-test analysis was used to determine the significance of the analysis. DLD1_NoORF:
3.914  3.037; DLD1_ABCA1: 20.92  6.231. The experiment was performed three times; 10–20 spheroids were quantified. Scale bars
correspond to 100 lm. (C) Levels of expression of E-cad and Vim mRNA. The values in the histograms correspond to mean  SEM. The
significance of differences between experimental groups was determined by t-test. For E-cad, DLD1_NoORF: 1.003  0.003161;
DLD1_ABCA1: 0.6925  0.02835. For Vim, DLD1_NoORF: 0.9942  0.009214; DLD1_ABCA1: 1.515  0.07528.
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processing the excess of cholesterol and reversing the
malignant phenotype driven by ABCA1 overexpres-
sion. Two additional stable cell lines were generated to
overexpress either APOA1 or both genes ABCA1 and
APOA1 in the same population. First, when cell prolif-
eration was analyzed, APOA1-overexpressing cells
showed proliferation rates that were comparable to
those of the control (Fig. 6A). When both genes were
upregulated, the high proliferation displayed under
ABCA1 overexpression was reversed by the presence
of high levels of APOA1 (Fig. 6A). In the same direc-
tion, overexpression of APOA1 was able to reduce the
basal levels of invasion present in DLD1 control cells
and ABCA1 overexpression phenotype was partially
rescued in the presence of the APOA1 (Fig. 6B). To
determine whether APOA1 in the extracellular com-
partment would be able to compensate for the malig-
nant features derived from ABCA1 overexpression, we
used human recombinant APOA1 (hAPOA1) and
monitored cell proliferation, migration and invasive
capacities. First, hAPOA1 was able to reduce the pro-
liferation rate of DLD1_ABCA1 and Caco-2ABCA1
cells at levels that were comparable to those of the
control (Figs 6C and S4). Together with this, a signifi-
cant decrease in cell migration was observed upon
hAPOA1 treatment (Fig. 6D). Furthermore, hAPOA1
compromised the invasiveness of both DLD1_NoORF
and DLD1_ABCA1 cell lines (Fig. 6D). When the
levels of CAV-1 were monitored by Western blot, a
clear reduction in its levels was detected upon treat-
ment with hAPOA1 (Fig. 6E), accompanied by a
reduction in ABCA1 protein levels (Fig. 6E). APOA1
overexpression has been associated with the inhibition
of COX-2 expression in hepatocytes (Mao et al.,
2014); as COX-2 inhibition is known to be able to
downregulate both ABCA1 mRNA and protein (Chan
et al., 2007), we analyzed the levels of the COX-2 in
our model. The addition of hAPOA1 in
DLD1_ABCA1 cells gave rise to a significant decrease
in COX-2 mRNA levels, accompanied by a significant
decrease in ABCA1 (Fig. 6F). Thus, APOA1 overex-
pression reverses ABCA1-derived malignant features
not only by direct regulation of exported cholesterol
but also by downregulating COX-2, therefore reducing
ABCA1 protein levels.
3.6. Apabetalone as a putative treatment for
invasive CRC
In 2010, Resverlogix developed a new molecule, apa-
betalone (RVX-208), a BET inhibitor originally discov-
ered in a screening for APOA1 mRNA inducers in
cultured hepatocytes (Gilham et al., 2016; McNeill,
2010). RVX-208 is the most advanced BET inhibitor in
clinical development. While this manuscript was in
preparation, apabetalone was entered in a Phase 3 clini-
cal trial for high-risk cardiovascular disease (CVD)
patients with type 2 diabetes mellitus and low HDL
(BETonMACE). Therefore, considering that RVX-208
could mimic hAPOA1 effect and to test whether it could
be included as a complementary treatment for CRC
patients, we analyzed whether ABCA1-dependent
malignant features could be ameliorated by the RVX-
208 mechanism of action. First, cells treated with the
drug increased in size and displayed morphological fea-
tures resembling those of epithelial cells (data not
shown). Treated cells presented a significant decrease in
VIM expression in both control and ABCA1-
Fig. 5. ABCA1 overexpression stabilizes CAV-1, affecting the dynamics of cellular focal adhesions. Malignant phenotypes driven by ABCA1
were reversed by APOA1. (A) ABCA1, CAV-1 and RHOA protein levels in DLD1 stable cell lines. Caveolae staining by CAV-1 immunoblotting
is shown on the left-hand panel. DNA is shown in blue; CAV-1 is shown in red. (B) FA areas were measured by vinculin immunostaining.
Both DLD1 (upper panel) and Caco-2 cell lines (lower panel) are shown. Scale bars correspond to 20 lm; r.u., relative units. The experiment
was performed three times. For each experiment, 10 pictures were taken and the number of FA was normalized against the number of
cells present in the field. The error bars in the histograms correspond to SEM. The significance of the differences between groups was
determined by t-test analysis. DLD1_NoORF: 1.000  0.02838; DLD1_ABCA1: 1.252  0.03057. Caco-2_NoORF: 1.244  0.01248, Caco-
2_ABCA1: 1.305  0.007392. (C) Correlation between CAV-1 and ABCA1 mRNA expression in SII- and SIII-CRC patients. (D) Protein levels
upon MbCD (4 mM) treatment in DLD1 cells. (E) Migration and invasiveness under MbCD treatment assessed in both DLD1 (left-hand
histograms) and Caco-2 (right-hand histograms) cell lines. n = 3. For each experiment, every condition was analyzed in duplicate; six fields
per transwell were quantified. The error bars in the histograms correspond to SEM. The significance of differences between groups was
determined by t-test analysis. In the migration analysis with DLD1 cells, the following results were statistically significant: DLD1_ABCA1
control: 1.000  0.07007, DLD1_ABCA1 + MbCD: 0.4931  0.07956. For Caco-2 cells: Caco-2_ABCA1 control: 1.000  0.1276; Caco-
2_ABCA1 + MbCD: 0.5360  0.1169. Analysis of invasion in DLD1 cells: DLD1_NoORF control: 1.041  0.08831, DLD1_NoORF+MbCD:
0.7689  0.09205; DLD1_ABCA1 control: 1.063  0.03943; DLD1_ABCA1 + MbCD: 0.9050  0.04589. (F) Analysis of focal adhesion size
using vinculin detection and quantification. Cells treated with the vehicle and with MbCD (4 mM) cells are shown. The experiment was
performed three times. For each experiment, 10 pictures were taken and the number of FA was normalized against the number of cells
present in the field. Mean  SEM. The significance of differences between groups was determined by t-test analysis. DLD1_ABCA1 control
cells: 1.000  0.02838; DLD1_ABCA1 + MbCD: 1.192  0.03278.
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overexpressing DLD1 cells (Fig. 7A, left-hand panels).
Together with this, DLD1_ABCA1 cells displayed sig-
nificantly higher levels of E-CAD (Fig. 7A, right-hand
panels). Thus, RVX-208 could revert the EMT pheno-
type present in cells overexpressing the cholesterol trans-
porter. In addition, proliferation rates were slower upon
drug treatment in terms of slowed proliferation rates in
both DLD1 and Caco-2 cell lines (Fig. 7B). When cells
overexpressing ABCA1 were treated with RVX-208,
ABCA1 protein levels decreased to levels comparable to
those in control cells (Fig. 7C). Moreover, RVX-208
compromised the stability of CAV-1, causing a reduc-
tion in its total protein levels (Fig. 7C). Migration of
both DLD1 and Caco-2 cells was reduced (Fig. 7D). A
significant decrease in invasiveness was also observed in
DLD1_NoORF, DLD1_ABCA1 and Caco-2_ABCA1
(Fig. 7D). Thus, the invasive capacities of
DLD1_ABCA1 and Caco-2_ABCA1 returned to nor-
mal levels after treatment with the BET inhibitor, indi-
cating putative therapeutic effects of this drugs in CRC
patients. Importantly, treatment with RVX-208 signifi-
cantly decreased cholesterol transport in both control
cells and DLD1_ABCA1 (Fig. 7E). Therefore, the BET
inhibitor can target RCT and attenuate malignant fea-
tures in human CRC-derived cells. As happened under
hAPOA1 treatment, we also observed that COX-2
expression was significantly decreased after treatment
with RVX-208 (Fig. 7F). To demonstrate that the res-
cue of the malignant phenotype was due to APOA1
expression, we used short hairpin RNA. Upon downreg-
ulation of APOA1, cell proliferation rates were signifi-
cantly increased in both control (Fig. 8A) and
DLD1_ABCA1 cells (Fig. 8B). When cells silenced for
APOA1 and treated with RVX-208 were interrogated
for invasiveness, a significant reversion of the RVX-208
effect was observed in both DLD1 control cells
and in cells overexpressing ABCA1 (Fig. 8C). This
demonstrates that the decreased malignancy driven by
the BET inhibitor RVX-208 depends on the up-regula-
tion of APOA1 and, in its capacity to regulate ABCA1,
CAV-1 stability and RCT.
4. Discussion
The discovery of new biomarkers that would allow the
identification and characterization of the initial steps
of tumorigenesis, as well as the prediction of disease
progression early on, has become of vital importance.
Several studies have demonstrated the implication of
lipid metabolism regulation in the promotion of migra-
tion (Jiang et al., 2015), invasion (Fisher et al., 2006;
Sanchez-Martınez and Cruz-Gil, 2015) and angiogene-
sis, three basic steps of metastasis formation. The
results published by Fernandez and collaborators
together with our previous results concerning the
ColoLipidGene signature, support our hypothesis that
ABCA1 could be considered a gene associated with a
poor prognosis. We have been able to demonstrate
that ABCA1 overexpression leads to EMT and
increased invasion. Importantly, equal results were
obtained with two cell lines that have been classified
inside two distinct consensus molecular subtypes
(CMS)-DLD1 as CMS1 and Caco-2 as CMS4. These
results obtained in vitro, are consistent with our study
performed with patients, where overexpression of
ABCA1 was associated with overall survival indepen-
dently of the molecular subtype of the cancer (Fernan-
dez et al., 2017).
Although we did not focus our research on the
structure of the plasma membrane, the implications of
an increased presence of ABCA1 together with CAV-1
stabilization on the plasticity of the plasma membrane
cannot be ignored. The increased amount of choles-
terol in the membrane derived from ABCA1
Fig. 6. The presence of endogenous and exogenous APOA1 indicated a reduction in cell proliferation and decreased invasiveness by
ABCA1 downregulation and CAV-1 reduction. (A) Cell proliferation of DLD1 and Caco-2 cells overexpressing ABCA1 and APOA1 alone or in
the same population (DLD1_Double). The values in the histograms correspond to mean  SEM. The significance of differences between
experimental groups was determined by t-test. (B) MatrigelTM-coated transwell analysis for invasiveness relative to control DLD1_NoORF
cells. The values in the histograms correspond to mean  SEM. The significance of differences between experimental groups was
determined by t-test. (C) Proliferation rate plots under hAPOA1 treatment. (D) Migration and invasion assays in cells treated with human
recombinant APOA1. n = 3. For each experiment, every condition was analyzed in duplicate; six fields per transwell were quantified. The
values in the histograms correspond to mean  SEM. The significance of differences between experimental groups was determined by t-
test. DLD1_NoORF+DMSO: 1.026  0.1288; DLD1_NoORF+hAPOA1: 0.4850  0.05796. DLD1_ABCA1 + DMSO: 1.002  0.08675;
DLD1_ABCA1 + hAPOA: 0.6076  0.1068. (E) Western blot for ABCA1 and CAV-1 detection in cells treated and not treated with hAPOA1
(80 lgmL1). (F) Quantitative real-time PCR for the detection of COX-2 mRNA in the presence of hAPOA1. In the histogram on the right,
the levels of ABCA1 mRNA expression are shown for control and DLD1_ABCA1 cells. The PCR was performed in triplicate with different
cell stocks. Each sample was analyzed in triplicate. The values in the histograms correspond to mean  SEM. The significance of
differences between experimental groups was determined by t-test. For migration, DLD1_NoORF + hAPOA1: 1.123  0.07083.
DLD1_ABCA1 + hAPOA1: 0.5527  0.06850. For invasion, DLD1_NoORF + hAPOA1: 0.8321  0.1226; DLD1_ABCA1 + hAPOA1:
0.5001  0.09493.
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Fig. 7. Treatment with apabetalone reverses the malignancy driven by ABCA1. (A) Levels of expression of EMT markers, Vim (left-hand
panels) and E-cad (right-hand panels). Cells were treated with RVX-208 (40 lM) or DMSO as control. The values in the histograms
correspond to mean  SEM. The significance of differences between experimental groups was determined by t-test. Each analysis was
performed by triplicate. (B) Growth curve analysis and quantification. Both vehicle-treated and RVX-208-treated cells were plotted. n = 3.
D_NoORF = DLD1_NoORF; D_ABCA1 = DLD1_ABCA1; C_NoORF = Caco-2_NoORF; C_ABCA1 = Caco2_ABCA1 cells. The values in the
histograms correspond to mean  SEM. The significance of differences between experimental groups was determined by t-test. (C)
ABCA1, APOA1 and CAV-1 protein levels upon RVX-208 treatment; a-tubulin was used as loading control. (D) Quantification of migration
and invasion assays, both in DLD1 (black) or Caco-2 (grey) control cells and cells overexpressing ABCA1. n = 3. For each experiment, every
condition was analyzed in duplicate; six fields per transwell were quantified. (E) Cholesterol efflux analysis in DLD1 control (black) cells and
cells overexpressing ABCA1 (grey). The experiment was performed in triplicate, and for each repetition, every condition was analyzed in
triplicate. (F) mRNA levels of COX-2 together with immunodetection of ABCA1 and CAV-1 by Western blot. Vinculin was used as loading
control.
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overexpression could affect the size of raft domains
and the composition of the membrane, its fluidity and
flexibility, with consequential implications for cell
mobility and cell signalling (Guerra et al., 2016).
According to the data presented here, before diagnosis,
ABCA1 can be considered a high-risk factor that
promotes tumour growth and dissemination of the pri-
mary lesion.
The BET inhibitors have already been proposed as
suppressors of tumorigenesis in several types of cancers
(Cheng et al., 2013; Puissant et al., 2013; Shi et al.,
2014). Among these kind of inhibitors, apabetalone is
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Fig. 8. APOA1 silencing reversed the phenotype promoted by RVX-208. (A) Cell proliferation assay in control cells treated with DMSO and
RVX-208 (80 lM). Scr, scrambled shRNA; shApoA1, short hairpin RNA against APOA1 expression. The histogram represents the slopes of
the curves. DLD1_NoORF transfected with shApoA1 and DMSO; in red, DLD1_NoORF transfected with shAPOA1 and treated with RVX-
208. The values in the histograms correspond to mean  SEM. Significance between experimental groups were determined by t-test. (B)
Cell proliferation assay in ABCA1 overexpressing cells treated with DMSO and RVX-208. Scr: scrambled short hairpin RNA; shAPOA1: short
hairpin RNA against APOA1 expression. The histogram represents the slopes of the curves. (C) Invasion assay performed in DLD1 cells.
Left panel represents DLD1_NoORF data; right-hand panel corresponds to DLD1_ABCA1. n = 3. For each experiment, every condition was
analyzed in duplicate; six fields per transwell were quantified.
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the most advanced in its clinical development (Phase
III) and is aimed at high-risk CVD patients with type 2
diabetes mellitus and low HDL. Up to 86% of Phase
III clinical trials are considered safe for patients with
alimentary, central nervous system, cardiovascular and
oncological diseases (Harrison, 2016). As a CVD-
related trial, the probability of apabetalone reaching
the next phase is around 55%. Although the trial of
apabetalone has not been completed at present, the
advanced phase that has not been reached, together
with our results, suggest a potential clinical benefit of
this drug. Notably, the drug concentration used in our
experiments is equivalent to the usage already pub-
lished for hepatocytes in a study proposing RVX-208
as treatment for atherosclerotic CVD (Gilham et al.,
2016). In our two cellular models, apabetalone treat-
ment was equally efficient against invasiveness, indicat-
ing that the drug could be efficient in a wide spectrum
of patients. One of the main effects of this resveratrol-
derived drug is the increase in APOA1 transcription.
An anti-tumorigenic activity of this lipoprotein has
already been described against melanoma (Zamanian-
Daryoush et al., 2013a) as well showing a protective
role against the development of a variety of lung dis-
eases, including lung cancer (Gordon et al., 2016).
Moreover, several studies have shown that APOA1
levels can be considered a biomarker with reduced
plasma levels in patients with early stage ovarian can-
cer compared with normal individuals (Clarke et al.,
2011; Kim et al., 2012; Kozak et al., 2003; Moore
et al., 2006). Lower serum APOA1 levels were also
associated with higher risk of breast cancer as well as
breast cancer recurrence (Chang et al., 2007) (Lane
et al., 1995). The exact mechanism by which APOA1
can modulate tumour malignancy is not yet fully
understood. One of the hypotheses is that APOA1 is
implicated in the biology of the tumour microenviron-
ment (Zamanian-Daryoush et al., 2013). Consistent
with our results demonstrating that hAPOA1 treatment
attenuates ABCA1-driven phenotypes, we also showed
that, through APOA1 up-regulation, RVX-208 dimin-
ishes cell malignancy in CRC-derived cells. We propose
here that the imbalance in the expression of ABCA1
and APOA1 is responsible for the malignant features
deriving from ABCA1 overexpression. The fact that
the high basal levels of ABCA1 in Caco-2, a cell line
with low rates of proliferation and low invasive capaci-
ties, are accompanied by high levels of APOA1 sup-
ports our hypothesis that disturbing this balance by a
further increase of ABCA1 leads to increased prolifera-
tion and invasiveness. As APOA1 could be easily
detected in human plasma, the increased concentration
of the protein in plasma extracted from CRC patients
could be used as marker of treatment efficacy. RVX-
208 treatment modulates ABCA1 expression, regulates
CAV-1 stability and controls RCT.
Further efforts and resources should be directed
towards acquiring knowledge of cholesterol balance
and cancer progression. Both cell autonomous effects
and their role in the tumour microenvironment may be
crucial to fully understand the importance of choles-
terol metabolism in cancer prognosis.
5. Conclusions
The expression levels of the cholesterol transporter
ABCA1 can be considered new prognosis markers for
colorectal cancer malignancy. ABCA1 overexpression
leads to EMT, and promotes migration and increases
invasive capacities by regulating CAV-1 stability. By
modulating ABCA1 expression and cholesterol pro-
cessing, APOA1 is able to reverse the malignant phe-
notypes displayed by cells overexpressing the RCT
regulator. Thus, intracellular cholesterol metabolism
and the apolipoprotein APOA1 emerge as new rele-
vant players in CRC progression to metastasis. Based
on these results, we propose here, for the first time,
the potential use of apabetalone, a stimulator of
APOA1 so far only considered for CVD, as a bona
fide inhibitor of colorectal cancer invasiveness.
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